Cancer statistics, 2025
- PMID: 39817679
- PMCID: PMC11745215
- DOI: 10.3322/caac.21871
Cancer statistics, 2025
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2021) and mortality data collected by the National Center for Health Statistics (through 2022). In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2022, averting nearly 4.5 million deaths since 1991 because of smoking reductions, earlier detection for some cancers, and improved treatment. Yet alarming disparities persist; Native American people bear the highest cancer mortality, including rates that are two to three times those in White people for kidney, liver, stomach, and cervical cancers. Similarly, Black people have two-fold higher mortality than White people for prostate, stomach, and uterine corpus cancers. Overall cancer incidence has generally declined in men but has risen in women, narrowing the male-to-female rate ratio (RR) from a peak of 1.6 (95% confidence interval, 1.57-1.61) in 1992 to 1.1 (95% confidence interval, 1.12-1.12) in 2021. However, rates in women aged 50-64 years have already surpassed those in men (832.5 vs. 830.6 per 100,000), and younger women (younger than 50 years) have an 82% higher incidence rate than their male counterparts (141.1 vs. 77.4 per 100,000), up from 51% in 2002. Notably, lung cancer incidence in women surpassed that in men among people younger than 65 years in 2021 (15.7 vs. 15.4 per 100,000; RR, 0.98, p = 0.03). In summary, cancer mortality continues to decline, but future gains are threatened by rampant racial inequalities and a growing burden of disease in middle-aged and young adults, especially women. Continued progress will require investment in cancer prevention and access to equitable treatment, especially for Native American and Black individuals.
Keywords: cancer cases; cancer statistics; death rates; incidence; mortality.
© 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
Conflict of interest statement
Rebecca L. Siegel, Tyler B. Kratzer, Angela N. Giaquinto, Hyuna Sung, and Ahmedin Jemal are employed by the American Cancer Society, which receives grants from private and corporate foundations, including foundations associated with companies in the health sector, for research outside of the submitted work. The authors are not funded by or key personnel for any of these grants, and their salary is solely funded through American Cancer Society funds. The authors disclosed no conflicts of interest.
Figures








Similar articles
-
Cancer statistics, 2024.CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. CA Cancer J Clin. 2024. PMID: 38230766
-
Cancer statistics for African American and Black people, 2025.CA Cancer J Clin. 2025 Mar-Apr;75(2):111-140. doi: 10.3322/caac.21874. Epub 2025 Feb 20. CA Cancer J Clin. 2025. PMID: 39976243 Free PMC article.
-
Cancer statistics, 2023.CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763. CA Cancer J Clin. 2023. PMID: 36633525
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
-
Cancer statistics, 2004.CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. CA Cancer J Clin. 2004. PMID: 14974761 Review.
Cited by
-
Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.Cancers (Basel). 2025 Feb 11;17(4):604. doi: 10.3390/cancers17040604. Cancers (Basel). 2025. PMID: 40002199 Free PMC article. Review.
-
Genetically predicted benign prostate hyperplasia causally affects prostate cancer: a two-sample Mendelian randomization.Transl Androl Urol. 2025 Mar 30;14(3):661-668. doi: 10.21037/tau-2024-673. Epub 2025 Mar 26. Transl Androl Urol. 2025. PMID: 40226058 Free PMC article.
-
Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study.Front Oncol. 2025 Apr 4;15:1530793. doi: 10.3389/fonc.2025.1530793. eCollection 2025. Front Oncol. 2025. PMID: 40255431 Free PMC article.
-
Synthesis, Characterization, and Preliminary In Vitro Anticancer Activity of Zinc Complexes Containing Amino Acid-Derived Imidazolium-Based Dicarboxylate Ligands.Int J Mol Sci. 2025 Mar 30;26(7):3202. doi: 10.3390/ijms26073202. Int J Mol Sci. 2025. PMID: 40244013 Free PMC article.
-
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma.Mol Cancer. 2025 Apr 22;24(1):121. doi: 10.1186/s12943-025-02315-9. Mol Cancer. 2025. PMID: 40264130 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical